Fablyn Panel Finds Mortality Trend Inconclusive, But Pfizer Ready With A Plan

FDA's Advisory Committee for Reproductive Health Drugs did not reach a clear conclusion on whether Pfizer's osteoporosis drug Fablyn has a mortality issue - but Pfizer already has a proposal for a post-market study to provide a definitive answer